# Aurobindo Pharma receives final approval for Alendronate Sodium Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Alendronate Sodium Tablets USP 10mg, 35mg and 70mg. This is a Paragraph IV certification.

Alendronate Sodium Tablets are the generic equivalent of Merck & Co Inc's Fosamax® Tablets USP 10mg, 35mg and 70mg, which are indicated for the treatment of Osteoporosis (bone disease). Annual sales of Alendronate Sodium Tablets USP 10mg, 35mg and 70mg in the US were approximately US$ 1,982 Million for the twelve months ending Dec 2007 according to Merck's Financial Disclosures

Aurobindo is in the first line of generics and got the USFDA nod on the very first day post the expiry of the relevant patent and the product will be launched immediately in the US market. This has been one of fastest approvals received by the company, within 8 months of the date of filing

This is Aurobindo's 73rd ANDA approval from the USFDA.

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.

**For further information, please contact:**
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com